Telix Doses First Patient In Phase 3 LUTEON Trial For Kidney Cancer Therapy TLX250-Tx

Telix has announced that the first patient has been treated with TLX250-Tx (lutetium-177 [177Lu] girentuximab tetraxetan) as part of the Phase 3 LUTEON clinical trial. The study marks an important milestone, as it is the first Phase 3 trial evaluating a radiopharmaceutical therapy for patients with relapsed or recurrent clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer. LUTEON is a randomized, prospective, open-label, multi-center study designed to assess the safety and effectiveness of this investigational treatment, which targets the CAIX protein commonly found in ccRCC tumors.

The first patient received the investigational therapy at GenesisCare Murdoch in Western Australia under the supervision of Dr. Aviral Singh, who serves as the site's Principal Investigator for the LUTEON trial. The study is expected to enroll patients across multiple clinical centers and will help generate important data on the potential role of targeted radiopharmaceutical therapy in treating advanced kidney cancer.

Dr. Aviral Singh, Clinical Head of Theranostics and Nuclear Medicine at GenesisCare Murdoch, said that dosing the first patient represents a significant step in developing new treatment options for individuals with relapsed or recurrent clear cell renal cell carcinoma. He noted that although treatment options for kidney cancer have improved over the years, many patients continue to experience poor outcomes, highlighting the need for more effective therapies. According to Dr. Singh, the LUTEON study will play an important role in evaluating the safety, tolerability, and clinical effectiveness of the investigational CAIX-targeted radiopharmaceutical for patients worldwide while contributing valuable evidence for its future development.

Dr. David N. Cade, Telix Group Chief Medical Officer, said the launch of the Phase 3 trial reflects the company's continued commitment to developing precision radiopharmaceutical treatments for cancers that are difficult to manage. He explained that TLX250-Tx has been designed to target carbonic anhydrase IX (CAIX), a protein that is highly expressed in most cases of clear cell renal cell carcinoma. By delivering radiation directly to cancer cells while minimizing exposure to surrounding healthy tissue, the therapy aims to improve treatment precision and reduce unnecessary damage to normal organs.

The LUTEON study represents the next stage in Telix's global clinical development program for TLX250-Tx. If successful, the trial could support the development of a new targeted treatment option for patients whose disease has returned or progressed after previous therapies. The study is expected to provide critical clinical data on the therapy's ability to improve outcomes while maintaining an acceptable safety profile.

With the first patient now enrolled and treated, Telix has reached an important milestone in advancing targeted radiopharmaceutical therapies for kidney cancer. The company believes that combining precision imaging and targeted radiation has the potential to improve the management of clear cell renal cell carcinoma and provide a more personalized treatment approach for patients facing limited options after disease recurrence.